DMPD Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €47.97 |
| 52 Week High | €47.97 |
| 52 Week Low | €36.74 |
| Beta | 1.14 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 0.31% |
| 5 Year Change | 111.79% |
| Change since IPO | 70.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMPD | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.3% |
| 1Y | n/a | -4.5% | 4.3% |
Return vs Industry: Insufficient data to determine how DMPD performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DMPD performed against the UK Market.
Price Volatility
| DMPD volatility | |
|---|---|
| DMPD Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DMPD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DMPD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,404 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products.
Dermapharm Holding SE Fundamentals Summary
| DMPD fundamental statistics | |
|---|---|
| Market cap | €2.01b |
| Earnings (TTM) | €122.56m |
| Revenue (TTM) | €1.15b |
16.4x
P/E Ratio1.7x
P/S RatioIs DMPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMPD income statement (TTM) | |
|---|---|
| Revenue | €1.15b |
| Cost of Revenue | €432.56m |
| Gross Profit | €718.65m |
| Other Expenses | €596.09m |
| Earnings | €122.56m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 15, 2023
| Earnings per share (EPS) | 2.28 |
| Gross Margin | 62.43% |
| Net Profit Margin | 10.65% |
| Debt/Equity Ratio | 207.6% |
How did DMPD perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yield46%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/13 17:11 |
| End of Day Share Price | 2023/08/16 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dermapharm Holding SE is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Daniel Wendorff | Commerzbank AG |
| Fabian Piasta | Jefferies LLC |